Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02203838 · ClinicalTrials.gov registry record · Phase 3
Long Term Study of RBP 7000 in the Treatment of Subjects With Schizophrenia
A Phase 3 study, sponsored by Indivior.
- Completed
- Registry status
- Phase 3
- Development phase
- 500
- Enrollment target
NCT02203838 is a Phase 3 study that has completed, run by Indivior. The registered enrollment target is 500 participants.
The verdict
NCT02203838, a Phase 3 study, has completed, sponsored by Indivior.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 500 participants
- Enrollment target
Study Summary
This is a Phase 3, open label study administering RBP-7000 in the treatment of patients with schizophrenia. Study will assess the long-term safety and tolerability of RBP-7000 subcutaneous (SC) injections in subjects with schizophrenia and to continue collecting clinical outcome data with RBP-7000 SC injections in subjects with schizophrenia using the Positive and Negative Syndrome Scale (PANSS) and Clinical Global Impression-Severity Illness (CGI-S) scale.
Interventions
- DRUG RBP-7000
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2014-06 |
| Est. Completion | 2016-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02203838
The ClinicalTrials.gov registry entry for NCT02203838 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Indivior, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which RBP-7000 is the first listed.
NCT02203838 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02203838 about?
NCT02203838 is a clinical study titled "Long Term Study of RBP 7000 in the Treatment of Subjects With Schizophrenia". This is a Phase 3, open label study administering RBP-7000 in the treatment of patients with schizophrenia. Study will assess the long-term safety and tolerability of RBP-7000 subcutaneous (SC) injections in subjects with schizophrenia and to continue collecting clinical outcome data with RBP-7000 S...
What is the current status of trial NCT02203838?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 500 participants. The study started on 2014-06. Estimated completion is 2016-09.
What interventions are being tested in trial NCT02203838?
The interventions under investigation include: RBP-7000 (DRUG).
Who is sponsoring clinical trial NCT02203838?
This trial is sponsored by Indivior, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.